FATE THERAPEUTICS INC

Fate Therapeutics Appoints Brian T. Powl as Chief Commercial Officer

30 Jun 2022 15:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Announces Expansion of Solid Tumor Collaboration with ONO Pharmaceutical for Off-the-Shelf, iPSC-derived CAR NK and CAR T-Cell Cancer Immunotherapies

28 Jun 2022 06:00:00 By Nasdaq GlobeNewswire

Fate Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference

03 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Fate Therapeutics to Present at Upcoming May Investor Conferences

06 May 2022 15:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Reports First Quarter 2022 Financial Results and Highlights Operational Progress

04 May 2022 15:01:01 By Nasdaq GlobeNewswire

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2022 Financial Results

22 Apr 2022 07:00:00 By Nasdaq GlobeNewswire

Fate Therapeutics to Present at Upcoming March Investor Conferences

02 Mar 2022 15:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Operational Progress

28 Feb 2022 15:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2021 Financial Results

16 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Fate Therapeutics to Present at Upcoming February Investor Conferences

02 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Fate Therapeutics Announces FDA Clearance for FT536, a First-in-class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors

10 Jan 2022 07:00:03 By Nasdaq GlobeNewswire

Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell Lymphoma at 2021 ASH Annual Meeting

13 Dec 2021 15:31:00 By Nasdaq GlobeNewswire

Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516 for Relapsed / Refractory DLBCL

13 Dec 2021 08:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics to Host Virtual Event at the 2021 ASH Annual Meeting

08 Dec 2021 16:44:52 By Nasdaq GlobeNewswire

Fate Therapeutics to Present at Upcoming Investor Conferences

11 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Fate Therapeutics Announces Abstract Highlighting FT538 and FT573 Programs Selected for Presentation at SITC 2021 Annual Meeting Press Conference

09 Nov 2021 08:00:02 By Nasdaq GlobeNewswire

Fate Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Operational Progress

04 Nov 2021 15:01:01 By Nasdaq GlobeNewswire

Fate Therapeutics Announces Eight Presentations at the 2021 ASH Annual Meeting

04 Nov 2021 08:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2021 Financial Results

25 Oct 2021 07:00:01 By Nasdaq GlobeNewswire

Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual Meeting

01 Oct 2021 07:01:00 By Nasdaq GlobeNewswire